Brain–computer interfacing

Synchron Receives Green Light From FDA to Begin Breakthrough Trial of Implantable Brain Computer Interface in US

Retrieved on: 
Wednesday, July 28, 2021

Outcomes will include the use of the brain data to control digital devices and achieve improvements in functional independence.

Key Points: 
  • Outcomes will include the use of the brain data to control digital devices and achieve improvements in functional independence.
  • The FDA granted Breakthrough Device designation to Synchron in August 2020 .
  • We are thrilled to finally be launching a U.S. clinical trial this year, said Synchron CEO Thomas Oxley, MD, PhD.
  • Other implantable BCI approaches involve drilling into the skull and placing needle electrodes directly into the brain tissue, which can result in long term brain inflammation.

Elite Education Group International Ltd. Announces First Half Fiscal Year 2021 Financial Results and Operational Update

Retrieved on: 
Tuesday, July 13, 2021

MIDDLETOWN, Ohio, July 13, 2021 /PRNewswire/ -- Elite Education Group International Limited (Nasdaq:EEIQ) ("EEG"), a provider of comprehensive, one-stop education solutions for Chinese university students interested in study abroad programs in the US and other countries, today announced its first half financial results for the six months ended March 31, 2021 and an operational update.

Key Points: 
  • MIDDLETOWN, Ohio, July 13, 2021 /PRNewswire/ -- Elite Education Group International Limited (Nasdaq:EEIQ) ("EEG"), a provider of comprehensive, one-stop education solutions for Chinese university students interested in study abroad programs in the US and other countries, today announced its first half financial results for the six months ended March 31, 2021 and an operational update.
  • "Our revenue decreased for the first half of fiscal 2021 primarily due to the global Covid-19 pandemic that negatively impacted businesses around the world in 2020.
  • First Half 2021 Financial Results Ended March 31, 2021
    Revenueswere $3.1 million for the first half of fiscal 2021 compared to $6.1 million for the same period of 2020, representing a decrease of $3.0 million, or 49.4%.
  • The decrease was primarily due to the drop inrevenue in the first half of 2021 compared to the same period of 2020.

Vie Style launches Kickstarter for smart earphones that track and analyze mental state while listening to music

Retrieved on: 
Tuesday, July 6, 2021

TOKYO, July 6, 2021 /PRNewswire-PRWeb/ --Today, Vie Style launched a Kickstarter campaign for Vie Zonelightweight and portable EEG earphones co-developed with the University of Tokyo, KDDI, and NTT data.

Key Points: 
  • TOKYO, July 6, 2021 /PRNewswire-PRWeb/ --Today, Vie Style launched a Kickstarter campaign for Vie Zonelightweight and portable EEG earphones co-developed with the University of Tokyo, KDDI, and NTT data.
  • It's designed specifically for minimalist in-ear devices to detect a wider range of brain activity with high accuracy."
  • This is possible thanks to Vie Zone's in-ear smart sensing technology that picks up the user's brain waves and heart rate in real-time through electroencephalogram.
  • The Vie Zone campaign will launch on July 6, 2021 with an estimated delivery date of December 2021.

Adept Neuro Reaches Key Milestone in the Development of Novel Intracerebral Stereoelectroencephalography (SEEG) Electrodes

Retrieved on: 
Tuesday, July 6, 2021

DIXI Medical will be investing its second tranche into Adept Neuro well ahead of the previously scheduled date, as per its development agreement.

Key Points: 
  • DIXI Medical will be investing its second tranche into Adept Neuro well ahead of the previously scheduled date, as per its development agreement.
  • Adept Neuro is a joint venture between DIXI Medical and Aleva Neurotherapeutics developing a new generation of intracerebral stereoelectroencephalography (SEEG) electrodes to facilitate localization and thermocoagulation of epileptogenic zones.
  • The DIXI Medical story started back in the 1970s with the request from French physicians to develop dedicated electrodes for SEEG surgeries.
  • Over 40 years later, DIXI Medical still has the same focus on epilepsy care and SEEG electrodes.

Over $700 Million growth expected in EEG and EMG Devices Market during 2021-2025 | Technavio

Retrieved on: 
Monday, June 21, 2021

The EEG and EMG devices market is expected to grow by USD 706.20 million during 2021-2025, according to Technavio.

Key Points: 
  • The EEG and EMG devices market is expected to grow by USD 706.20 million during 2021-2025, according to Technavio.
  • The EEG and EMG devices market will witness a positive impact during the forecast period owing to the widespread growth of the COVID-19 pandemic.
  • Gain more insights about the global trends impacting the future of EEG and EMG devices market, Request Free Sample @ https://www.technavio.com/talk-to-us?report=IRTNTR40609
    Major Five EEG and EMG Devices Market Participants:
    Ambu AS:The company offers EEG and EMG equipment under the brand names Ambu Neuroline Cup, Ambu Neuroline Monopolar electrodes, Ambu Neuroline Concentric, and Ambu Neuroline 715.
  • EEG and EMG Devices Market 2021-2025: Segmentation
    EEG and EMG devices market is segmented as below:

Synchron Secures $40M in Series B led by Khosla Ventures to Launch U.S. Clinical Trials of Minimally Invasive Brain Computer Interface

Retrieved on: 
Thursday, June 3, 2021

Synchron, a brain interface platform company , today announced that the company has secured $40M in a Series B round of financing led by Silicon Valley venture capital firm Khosla Ventures.

Key Points: 
  • Synchron, a brain interface platform company , today announced that the company has secured $40M in a Series B round of financing led by Silicon Valley venture capital firm Khosla Ventures.
  • Synchron is the leader in minimally invasive implantable brain computer interface (BCI) technology, which utilizes the jugular vein to access the brain.
  • This technology has the potential to positively impact humanity on a vast scale, said Synchron CEO Thomas Oxley, MD, PhD.
  • Synchron, a brain interface platform company, is a leader in the field of implantable neural interface technology.

NeuroOne Introduces Advisory Board for Ablation Electrode Technology that Records and Ablates Brain Tissue Linked to Seizure Activity

Retrieved on: 
Wednesday, June 2, 2021

Their experience in the field will be indispensable to the Company in developing a product that allows neurologists to record brain activity and ablate targeted brain tissue in the same procedure.

Key Points: 
  • Their experience in the field will be indispensable to the Company in developing a product that allows neurologists to record brain activity and ablate targeted brain tissue in the same procedure.
  • The electrode is also expected to save time, cost and potentially improve outcomes, adding value to both patients and physicians that could benefit from this technology."
  • In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015.
  • NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson's disease, epilepsy and pain management due to failed back surgery procedures.

New commitment to supporting sex and gender-based brain research in Canada

Retrieved on: 
Tuesday, June 1, 2021

Sixgrantsof up to $105,000 will be awarded for a total investment of $630,000 in the amplification of sex and gender-based research.

Key Points: 
  • Sixgrantsof up to $105,000 will be awarded for a total investment of $630,000 in the amplification of sex and gender-based research.
  • Funding for the Brain Canada-WBHIExpansionGrant: Considering Sex and GenderProgram has been made possible by WBHI's annual Stand Ahead Challenge fundraising campaign, and through the Canada Brain Research Fund, an innovative partnership between the Government of Canada (through Health Canada) and Brain Canada.
  • Brain Canada is a national non-profit organization that enables and supports excellent, innovative, paradigm-changing brain research in Canada.
  • About Womens Brain Health Initiative:
    Womens Brain Health Initiative (WBHI) is a Canadian and U.S. charitable foundation established in 2012 and is solely dedicated to protecting the brain health of women.

Brain Scientific Receives Purchase Order and Begins Shipping Its Pediatric NeuroCap™ EEG Headsets

Retrieved on: 
Monday, May 24, 2021

We are happy to provide our pediatric EEG products to Maine Medical Center.

Key Points: 
  • We are happy to provide our pediatric EEG products to Maine Medical Center.
  • The NeuroCap for children is designed to address the need for comfort, speed and reliability within the pediatric population.
  • The Pediatric NeuroCap has 22 pre-gelled electrodes, in accordance with the 10-20 international system, and can be used for EEG studies up to four hours in length.
  • Brain Scientific is working to help better equip healthcare facilities nationwide with its easy-to-use solutions for children while providing convenience and comfort.

Optogenetic Methods Restore Partial Vision in a Blind Patient

Retrieved on: 
Monday, May 24, 2021

This is a milestone towards a gene therapy that could restore vision.

Key Points: 
  • This is a milestone towards a gene therapy that could restore vision.
  • A Media Snippet accompanying this announcement is available by clicking on the image:
    Paris, Pittsburgh, Basel, May 24th, 2021- Clinical trial results announced today show for the first time that optogenetic methods can partially restore vision in a blind human patient.
  • "The findings provide proof-of-concept that using optogenetic therapy to partially restore vision is possible" says last and corresponding author Botond Roska, Founding Director at IOB and Professor at the University of Basel.
  • To restore light-sensing capability, the team uses gene therapy methods to deliver channelrhodopsins into the retina's ganglion cells.